Lower-risk breast cancer screening draws cautious support from clinicians in MyPeBS
A personalized breast cancer screening strategy may sound straightforward in theory: identify women at lower risk and screen them less often. In practice, the idea triggers hesitation among the healthcare professionals closest to implementation. Within the MyPeBS study context, clinicians described the low-risk estimate as reassuring news for women, yet their support for extending screening intervals was far from uniform. The central tension was not whether individualized risk assessment can be done, but whether a reduction in screening frequency will be acceptable once it reaches the clinic and the screening letter.
Previous exposure to standard population screening shaped much of that hesitation. Clinicians repeatedly linked lower acceptance to the fact that many women have spent years learning that regular mammography is the expected pattern of care. A new message telling a woman she may now be invited less often challenges that familiar rhythm. In screening medicine, habit is not a trivial force; it is part of how trust, reassurance, and compliance are built over time.
Familiar screening habits shaped clinician concern about acceptance
The study used a qualitative interpretative descriptive design, with 12 health professionals interviewed individually and in a discussion group before the transcripts were examined through thematic analysis. Their responses pointed to a clear pattern: a lower-risk result was generally welcomed, but welcome did not automatically translate into acceptance of fewer screening visits. Some clinicians viewed the reduction in frequency as a logical consequence of a lower estimated risk. Others saw it as a harder sell, especially among women already accustomed to routine, repeated screening.
The hesitancy is clinically understandable. When patients have been taught that annual or regular screening is protective, any de-escalation can feel like a withdrawal of care rather than a smarter allocation of it. The psychological effect of changing interval length may be especially strong in preventive oncology, where the intervention is repeated over many years and the patient often remains asymptomatic. In that setting, perceived security can matter as much as statistical risk.
One sentence captured the practical challenge: prior participation in current screening emerged as the strongest influence on low acceptance of reduced frequency.
Equity and resource questions surfaced alongside the risk discussion
Healthcare professionals did not confine their concerns to patient preference. They also raised questions about whether a personalized model can be delivered equitably and sustainably. If screening intervals are altered according to risk, the system has to ensure that women are not sorted into pathways that differ in quality, clarity, or accessibility. Clinicians worried about how to guarantee equity across groups once screening stops being uniform.
Resource feasibility also entered the discussion. A personalized program is not simply a matter of changing a recommendation in a booklet. It requires risk calculation, communication, follow-up systems, and enough human and financial capacity to support a more tailored model. If those components are thin, a strategy designed to improve precision may instead increase confusion or create uneven uptake. The burden then shifts from a standardized invitation system to a more complex workflow that must still function at population scale.
These concerns matter because de-escalation can only work if clinicians believe the new pathway is safe, understandable, and deliverable without widening existing gaps. When a preventive program changes from one-size-fits-all to risk-adapted care, equity is not an abstract policy issue. It becomes part of the clinical encounter, the invitation process, and the public’s confidence in the program itself.
Why a lower-risk result does not automatically reduce anxiety
The MyPeBS context is important because the study is testing a broader idea: whether personalized screening can improve the balance between benefit and harm by adapting surveillance to individual risk. For women identified as lower risk, extending the interval may reduce exposure to unnecessary imaging, follow-up testing, and the downstream consequences of false-positive findings. In principle, fewer screens in a genuinely low-risk group should preserve benefit while limiting overdiagnosis and overtesting.
Yet risk communication in breast screening is rarely that clean. A woman told that her risk is lower may hear reassurance, but she may also hear that she is being deprioritized. Clinicians in this study implicitly recognized that the message has to do more than present probability; it has to preserve confidence in the screening program. The biological logic is sound, but screening behavior is shaped by psychology, prior experience, and institutional trust as much as by risk stratification.
That gap between statistical logic and patient acceptance is where implementation often stalls. A de-escalated interval can be justified on preventive grounds, but if women interpret the change as lost protection, the result may be poorer uptake or resistance to participation.
What the clinician interviews suggest for MyPeBS and beyond
The interview data point to a simple but consequential implementation problem: lower risk does not guarantee easier adoption. The professionals involved in MyPeBS saw the risk estimate itself as positive, yet they anticipated disagreement once the recommendation changed from regular screening to less frequent screening. Their concerns clustered around three areas—benefit, equity, and feasibility—and all three need to be addressed before personalized screening can move from concept to routine service.
Future work will need to refine how both clinicians and women understand the purpose of screening interval changes. If healthcare professionals remain uncertain about the benefits of de-escalation for lower-risk women, they may communicate the recommendation hesitantly, and hesitation is contagious. Women are more likely to accept a new pathway when the explanation is consistent, confident, and clearly tied to their individual risk profile.
The findings also leave practical questions open for program planners. How will systems deliver personalized screening without creating uneven access? How will clinicians explain why fewer mammograms can still be the right choice for some women? How much resource investment is required to make a personalized model workable rather than aspirational?
Those questions remain central to the MyPeBS effort, and they are likely to determine whether personalized breast cancer screening becomes a workable population strategy or remains a selective option resisted at the point of care.